Diabetes Vaccine Gives Promising Results in Clinical Study

Diabetes Vaccine Gives Promising Results in Clinical Study

A medical examine led by Linköping College and financed by prescribed drugs firm Diamyd Medical has investigated whether or not immunotherapy towards sort 1 diabetes can protect the physique’s personal manufacturing of insulin. The outcomes recommend that injection of a protein, GAD, into lymph nodes will be efficient in a subgroup of people. The outcomes have been revealed in Diabetes Care.

In sort 1 diabetes, the physique’s immune system assaults the cells that produce insulin. When the insulin-producing cells have disappeared, the physique can now not regulate blood sugar stage, and an individual with sort 1 diabetes should take exogenous insulin for the remainder of his or her life.

A extremely topical query in analysis into sort 1 diabetes is whether or not, and in that case how, the assault of the immune system will be slowed and even utterly stopped. One potential technique relies on altering the immune defence by injecting a protein that the cells of the immune system react to, in a type of vaccination. One of many proteins towards which the immune system typically varieties antibodies in sort 1 diabetes is called GAD65 (glutamic acid decarboxylase). Professor Johnny Ludvigsson at Linköping College has studied for a few years the potential of vaccinating individuals who have newly identified sort 1 diabetes with GAD. It’s hoped that the immune system will turn out to be extra tolerant towards the physique’s personal GAD, and cease damaging the insulin-producing cells, such that the physique can proceed to kind some insulin.

Johnny Ludvigsson, senior professor at Linköping College. Credit score: Anna Nilsen/Linköping College

“Research have proven that even an especially small manufacturing of insulin in the physique is extremely useful for affected person well being. Individuals with diabetes who produce a specific amount of insulin naturally don’t develop low blood sugar ranges, hypoglycaemia, so simply. They’ve additionally a decrease danger of growing the life-threatening situation ketoacidosis, which may come up when the insulin stage is low”, says Johnny Ludvigsson, senior professor in the Division of Biomedical and Clinical Sciences at Linköping College.

Johnny Ludvigsson has led DIAGNODE-2, a medical part 2 examine in which researchers investigated the impact of GAD-alum (Diamyd) injections into the lymph nodes of 109 younger folks with lately identified sort 1 diabetes. The pure insulin manufacturing of the contributors was measured initially of the examine and once more after 15 months. A number of different final result measures have been additionally adopted, comparable to change in long-term blood sugar ranges (HbA1c), and the way a lot supplementary insulin the sufferers wanted to take day by day.

Earlier research of immunotherapy in diabetes have prompt that genetic elements play a task in how sufferers reply to the therapy. This led the researchers in DIAGNODE-2 to have a look at a number of variants of what are generally known as “HLA genes.” These genes code for proteins positioned on the floor of some cells. They perform as holders of proteins, and expose them to immune system cells passing by. If the protein fragment uncovered in this fashion comes from, for instance, micro organism, the immune system ought to kind antibodies towards the international protein. Nonetheless, the immune system typically reacts towards the physique’s personal substances, and sure kinds of HLA are related to an elevated danger of sort 1 diabetes. The HLA variant HLA-DR3-DQ2 exposes the GAD65 protein to cells of the immune system, and sufferers with this variant typically kind antibodies towards GAD65 at an early stage of the illness. Round half of the contributors in the examine had the HLA-DR3-DQ2 variant.

For the whole affected person group, there was no distinction between therapy and placebo in the diploma to which insulin manufacturing was preserved. GAD-alum did, nevertheless, have a optimistic impact for the subgroup of sufferers who had the DR3-DQ2 variant of HLA genes.

“The sufferers in the subgroup with the DR3-DQ2 sort of HLA genes didn’t lose insulin manufacturing as shortly as the opposite sufferers. In distinction, we didn’t see any important impact in the sufferers who didn’t have this HLA sort”, says Johnny Ludvigsson.

No undesired results that might be associated to therapy with GAD-alum have been seen throughout the examine.

“Therapy with GAD-alum appears to be a promising, easy and secure solution to protect insulin manufacturing in round half of sufferers with sort 1 diabetes, those who’ve the suitable sort of HLA. For this reason we’re wanting ahead to finishing up bigger research, and we hope these will result in a drug that may change the progress of sort 1 diabetes”, says Johnny Ludvigsson.

The examine has been financed by Diamyd Medical AB, the Swedish Little one Diabetes Basis, and the Swedish Diabetes Basis. The pharmaceutical firm Diamyd Medical was concerned in planning and the gathering of information. One of many authors, Ulf Hannelius, is employed by Diamyd Medical.

The examine:

The 109 contributors, aged between 12 and 24 years, had been identified with sort 1 diabetes throughout the previous 6 months, and have been allotted at random to one in every of two teams. One group obtained three injections of GAD-alum at intervals of 1 month and vitamin D in pill kind, whereas the opposite group (controls) obtained placebo. Neither the contributors nor the researchers knew which sufferers obtained therapy with GAD-alum (the examine was randomized and double-blind).

Reference: “Intralymphatic glutamic acid decarboxylase with Vitamin D supplementation in latest onset Kind 1 diabetes: a double-blind randomized placebo-controlled Section IIb trial” by Johnny Ludvigsson, Zdenek Sumnik, Terezie Pelikanova, Lia Nattero Chavez, Elena Lundberg, Itxaso Rica, Maria A Martínez-Brocca, MariSol Ruiz de Adana, Jeanette Wahlberg, Anastasia Katsarou, Ragnar Hanas, Cristina Hernandez, Maria Clemente León, Ana Gómez-Gila, Marcus Lind, Marta Ferrer Lozano, Theo Sas, Ulf Samuelsson, Stepanka Pruhova, Fabricia Dietrich, Sara Puente Marin, Anders Nordlund, Ulf Hannelius and Rosaura Casas, 21 Might 2021, Diabetes Care.

Back to top button